Newsletter

226950 - Olix Pharmaceuticals, Inc.

226950 Summary
Biopharma
Stock Price & Overview
₩95,900 +4,100 (+4.47%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩95,900  ≈ US$69  ·  Market cap ₩2.0tn (≈ $1.4bn)

226950 Quarterly Results

Quarter ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
2026 Q22.6-58.0%-14.0-533.3%—-11.0₩-522
2026 Q13.6+265.8%-10.8-301.9%—-9.8₩-464
2025 Q44.5+9,920.3%-8.5-186.7%—15.4₩731
2025 Q32.9+1,002.6%-8.3-285.7%—-8.7₩-411
2025 Q26.3+35.9%-5.0-79.4%—-9.2₩-437
2025 Q11.0+27.1%-8.2-844.1%—-13.3₩-630
2024 Q40.0—-7.6-16,826.5%—-12.2₩-577
2024 Q30.3—-9.4-3,580.1%—-10.5₩-499
Three-month figures from DART consolidated statements. Q4 is the annual figure less the nine-month cumulative. EPS is net income over today's share count, so buybacks and issuance move earlier quarters. YoY compares with the same quarter a year earlier and is blank when that quarter was a loss.

226950 Annual Results

Full statements »
Fiscal year ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
FY202514.7+158.3%-30.0-204.4%—-15.7₩-747
FY20245.7-66.7%-30.9-544.6%—-40.7₩-1,930
FY202317.1+83.1%-18.2-106.6%—-19.1₩-907
FY20229.3+153.7%-22.4-240.1%—-21.9₩-1,039
FY20213.7+48.5%-24.2-659.4%—-30.3₩-1,438
FY20202.5+118.9%-16.2-656.4%—-19.4₩-920

226950 Next Report

The latest quarter on file is 2026 Q2. The next one, the Q3 2026 report covering the period to Sep 30, 2026, is due on DART by Nov 14, 2026 — Korean issuers must file quarterly and half-year reports within 45 days of period end and the annual report within 90 days.

Large issuers usually publish preliminary consolidated figures (잠정실적, a fair-disclosure filing with revenue and operating profit only) in the first weeks after the period ends, ahead of the full report. kstock does not know a company's chosen release date; when the preliminary filing arrives it appears under Filings and on this page.

226950 Earnings Filings

All filings »
DART

Half-Year Report

Periodic08/14/26title translated
DART

Quarterly Report

Periodic05/15/26title translated

How Korean earnings differ from US earnings

  • No quarterly guidance culture. Most KRX companies give no EPS or revenue guidance; the preliminary filing is the first number the market sees, and there is no consensus beat/miss ritual built around it.
  • Preliminary first, then the report. The 잠정실적 filing carries revenue and operating profit; net income and the balance sheet come with the full report weeks later.
  • Consolidated is the headline. Korean companies report consolidated (K-IFRS) and separate (parent-only) figures; kstock uses consolidated unless the page says otherwise.
  • Fiscal years end in December for almost every listed company, so Q4 is derived: the annual figure less the nine-month cumulative.

Similar to 226950

SymbolLast Price
009420Hanall Biopharma Co., Ltd.₩54,700
+1.5%
310210Voronoi, Inc.₩153,000
+3.9%
214370Caregen Co., Ltd.₩44,500
+1.5%
347850D & D Pharmatech, Inc.₩49,200
+1.4%
237690ST Pharm Co., Ltd.₩101,200
+2.2%
140410Mezzion Pharma Co., Ltd.₩65,000
+0.0%
068760Celltrion Pharm, Inc.₩40,850
+0.0%
007390Naturecell Co., Ltd.₩23,950
+0.2%
006280GC Biopharma Corp.₩127,600
+0.5%
950160Kolon Tissue Gene, Inc.₩17,100
+1.1%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.